2'-cyano-2'-deoxyarabinofuranosylcytosine has been researched along with Abnormalities, Autosome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cheng, N; Jiang, Y; Liu, X; Nowak, B; Plunkett, W; Qiang, B | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
2 other study(ies) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and Abnormalities, Autosome
| Article | Year |
|---|---|
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Synergism; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Tumor Stem Cell Assay | 2018 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |